Abstract
Risperidone is a novel antipsychotic agent that blocks both dopaminergic and serotonergic receptors. In several reports, clinically significant hyperprolactinemia has been reported in patients on this agent. However, the optimal management of risperidone-induced hyperprolactinemia has not been clarified. We reviewed the records of 5 patients with psychotic disorders who were evaluated for risperidone-induced hyperprolactinemia. There were 4 females and 1 male patient, aged 30–45 yr. All patients had significant hyperprolactinemia, with prolactin (PRL) levels ranging from 65.5 to 209 μg/l. All but 1 of these patients had manifestations of hypogonadism. In these 4 patients, risperidone therapy was continued and the dopamine agonists bromocriptine or cabergoline were added. In 3 out of 4 patients, such additional therapy reduced the PRL level and alleviated hypogonadism. None of the patients treated with these agents had a worsening of psychosis. We conclude that risperidone can cause clinically significant hyperprolactinemia in patients treated with this drug. If risperidone therapy must be continued in such patients, addition of the dopamine agonists bromocriptine or cabergoline may successfully alleviate hyperprolactinemia and the associated manifestations without worsening psychotic symptoms.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin. Pharmacol. 1992, 11: 851–856.
Dickson R.A., Glazer W.M. Neuroleptic-induced hyperprolactinemia. Schizophr. Res. 1999, 35: (Suppl.), S75–S86.
Marder S.R. Clinical experience with risperidone. J. Clin. Psychiatry 1996, 57: 57–61.
Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.I., Zylick 3. Z., Visscher H.W., Jonkman J.H.G. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 1993, 54: 257–268.
Shiwach R.S., Carmody T.J. Prolactogenic effects of risperidone in male patientsa preliminary study. Acta Psychiatr. Scand. 1998, 98: 81–83.
Caracci G. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J. Clin. Psychopharmacol. 1999, 19: 94–196.
Dickson R.A., Dalby J.T., Williams R., Edwards A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am. J. Psychiatry 1995, 152: 1102–1103.
Dickson R.A., Glazer W.M. Hyperprolactinemia and male sexual dysfunction. J. Clin. Psychiatry 1999, 60: 125.
Popli A., Gupta S., Rangwani S.R. Risperidone-induced galactorrhea associated with a prolactin elevation. Ann. Clin. Psychiatry 1998, 10: 31–33.
Kim Y-K. Kim L., Lee M-S. Risperidone and associated amenorrhea: a report of 5 cases. J. Clin. Psychiatry 1999, 60: 315–317.
Markianos M., Hatzimanolis J., Lykouras L. Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology 1999, 143: 270–272.
Breier A.F., Malhotra A.K., Tung-Ping S., Pinals D.A., Elman I., Adler C.M., Lafargue T., Clifton A., Pickar D. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am. J. Psychiatry 1999, 156: 294–298.
Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 1994, 331: 904–909.
Luis De Rivera J., Lal S., Ettigi P., Hontela S., Muller H.F., Friesen H.G. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin. Endocrinol. 1976, 5: 273–282.
Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999, 19: 57–61.
Parkes D. Drug Therapy. Bromocriptine. N. Engl. J. Med. 1979, 301: 873–878.
Beaumont P., Bruwer J., Pimstone B., Vinik A., Utian W. Bromo-ergocryptine in the treatment of phenothiazine-induced galactorrhea. Br. J. Psychiatry 1975, 126: 285–288.
Varia I.M., Cavenar J.O., Taska R.J., Maltbie A.M. Bromocriptine in the treatment of haloperidol-induced galactorrhea. N. C. Med. J. 1982, 43: 769–770.
Shenoy R.S., Etigi P., Johnson C.H. Bromocriptine in the treatment of galactorrhea caused by haloperidol: a case study. J. Clin. Psychopharmacol. 1983, 3: 187–188.
Siever L.J. The effect of amantadine on prolactin levels and galactorrhea on neuroleptic- treated patients. J. Clin. Psychopharmacol. 1981, 1: 2–7.
Correa N., Opler L.A., Kay S.R., Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J. Clin. Psychopharmacol. 1987, 7: 91–95.
Yamada K., Kanba S., Yagi G., Asai M. Herbal Medicine (Shakuyaku-kanzo-to) in the treatment of risperidone-induced amenorrhea. J. Clin. Psychopharmacol. 1999, 19: 380–381.
Sanfilippo J.S. Implications of not treating hyperprolactinemia. J. Reprod. Med. 1999, 44: 1111–1115.
Halbreich U., Rojansky N., Palter S., Hreshchyshyn M., Kreeger J., Bakai Y., Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 1995, 57: 485–491.
Kartaginer J., Ataya K., Mercado A., Abbasi A. Osteoporosis associated with neuroleptic treatment. A case report. J. Reprod. Med. 1990, 35: 198–202.
Author information
Authors and Affiliations
Corresponding author
Additional information
Portions of this work were presented at the 79th Annual Meeting of the Endocrine Society, June 11–14, 1997, Minneopolis, Minnesota.
Rights and permissions
About this article
Cite this article
Tollin, S.R. Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest 23, 765–770 (2000). https://doi.org/10.1007/BF03345068
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345068